secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001171843-26-001336
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics reports 2025 net loss of $66.5M; tovecimig PFS/OS data due in April
--------------------------------------------------------------------------------

- Net loss $66.5M ($0.42/share) vs $49.4M ($0.36/share) in 2024; R&D spend up 32% to $56.0M.
- Cash and marketable securities $209M as of Dec 31, 2025; expected runway into 2028.
- Tovecimig COMPANION-002 PFS/OS analyses expected in April 2026 after reaching 80% OS events.
- CTX-8371 expansion cohorts enrolling in TNBC and NSCLC; initial data expected Q2 2026.
- CTX-10726 IND cleared; Phase 1 enrolling in Q1 2026; Bing Gong promoted to CSO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184326001336/0001171843-26-001336-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184326001336/f8k_030326.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-001336

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer